Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 24,300 shares, an increase of 54.8% from the October 31st total of 15,700 shares. Based on an average daily trading volume, of 49,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Oculis in a report on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $29.20.

Oculis Price Performance

Shares of Oculis stock traded down $0.12 on Friday, hitting $16.04. The company’s stock had a trading volume of 32,043 shares, compared to its average volume of 37,117. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. Oculis has a 1 year low of $9.60 and a 1 year high of $18.00. The firm has a fifty day moving average price of $14.88 and a 200-day moving average price of $12.86. The company has a market capitalization of $649.62 million, a price-to-earnings ratio of -8.37 and a beta of -0.16.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The business had revenue of $0.27 million during the quarter, compared to analysts’ expectations of $0.28 million. As a group, sell-side analysts anticipate that Oculis will post -2.09 earnings per share for the current fiscal year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.